MAUTINO, Mario,KUMAR, Sanjeev,JAIPURI, Firoz,WALDO, Jesse,POTTURI, Hima,ZHUANG, Hong
申请号：
HK18107364
公开号：
HK1247837A1
申请日:
2018.06.06
申请国别(地区):
HK
年份:
2018
代理人:
摘要：
Presently provided are indoximod prodrug and salt compounds and pharmaceutical compositions comprising salts and prodrugs of indoximod, that produce enhanced plasma concentration and exposure to indoximod compared to direct administration of indoximod, in patients in need of treatment of immunosuppression mediated by the indoleamine-2,3-dioxygenase pathway, such as patients with cancer or chronic infectious diseases.
